

Intracellular *Salmonella* metabolism

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Dirk Bumann and Joep Schothorst

Focal Area Infection Biology, Biozentrum, University of Basel, CH-4056 Basel, Switzerland

dirk.bumann@unibas.ch

Abstract

Growth of *Salmonella* inside infected host cells is a key aspect of their ability to cause local enteritis or systemic disease. This growth depends on exploitation of host nutrients through a large *Salmonella* metabolism network with hundreds of metabolites and enzymes. Studies in cell culture infection models are unraveling more and more of the underlying molecular and cellular mechanisms, but also show striking *Salmonella* metabolic plasticity depending on host cell line and experimental conditions. In vivo studies have revealed a qualitatively diverse, but quantitatively poor, host-*Salmonella* nutritional interface, which on one side makes *Salmonella* fitness largely resilient against metabolic perturbations, but on the other side severely limits *Salmonella* biomass generation and growth rates. This review discusses goals and techniques for studying *Salmonella* intracellular metabolism, summarizes main results and implications, and proposes key issues that could be addressed in future studies.

21 **Introduction**

22 *Salmonella enterica* is a Gram-negative bacterium and a close relative of *Escherichia coli*.
23 There are more than two 2300 different *Salmonella* serovars, many of which can cause local
24 intestinal disease (enteritis, diarrhea) in a broad range of hosts. By contrast, some serovars
25 can also disseminate from the gut and cause systemic disease in a host-specific manner
26 (enteric fever / (para)typhoid fever, non-typhoidal salmonellosis NTS). *Salmonella* cause
27 major mortality and morbidity worldwide (Havelaar *et al.*, 2015, Keestra-Gounder *et al.*,
28 2015, LaRock *et al.*, 2015, Wain *et al.*, 2015). Vaccines for prevention of human disease are
29 available for the single serovar Typhi, and have only moderate protective efficacy.
30 Antimicrobial chemotherapy becomes less and less effective due to rapidly increasing
31 multidrug resistance, and both the US Center for Disease Control and the WHO include
32 *Salmonella* among the most serious infectious disease threats for human health. In addition to
33 better vaccines and novel antibiotics, interference with transmission by supplying clean
34 drinking water can dramatically reduce incidence of enteric fever, and better control of
35 *Salmonella* carriage in animal livestock might largely prevent diarrheal disease and NTS.

36 There are two main types of *Salmonella* infection, causing either enteritis or systemic
37 disease. Both infections start with ingestion of *Salmonella*-contaminated food or water. A
38 large part of the ingested *Salmonella* are killed by stomach acid, bile, and intestinal defensins
39 (Wotzka *et al.*, 2017). Neutrophils migrating through the gut mucosa also efficiently kill
40 *Salmonella* in the gut lumen, and neutrophils and macrophages in the gut mucosa kill
41 efficiently invading *Salmonella*. Nevertheless, if the infectious dose is large enough (i.e.,
42 higher than 1'000 to 100'000 colony-forming units) and competition by resident microbiota
43 is overcome, surviving *Salmonella* can overwhelm these defenses and cause disease in the
44 intestine. During enteritis, *Salmonella* proliferates mostly in the gut lumen, although some
45 *Salmonella* invade the intestinal mucosa and proliferate in gut epithelial cells (Wotzka *et al.*,

46 2017), and this is strongly enhanced in neonate mice (Zhang *et al.*, 2014). Intra-epithelial
47 *Salmonella* proliferation leads to inflammasome activation and extrusion of infected cells
48 (Knodler *et al.*, 2014, Sellin *et al.*, 2014, Zhang *et al.*, 2014), which might contribute to the
49 overall inflammation response which ultimately leads to water loss to the lumen and diarrhea
50 (Darwin *et al.*, 1999). However, the importance of this epithelial proliferation for enteritis
51 pathology and *Salmonella* overall fitness and transmission is still unclear.

52 *Salmonella* serovars that can cause systemic disease on the other hand, enter intestinal
53 Peyer's patches and solitary intestinal lymphoid tissue. In mouse models, *Salmonella* are
54 rarely found in epithelial cells of adult hosts (Halle *et al.*, 2007, Zhang *et al.*, 2014), whereas
55 in neonate mice, which largely lack differentiated M-cells, *Salmonella* mostly invade
56 epithelial cells and probably disseminate from there to internal organs (Zhang *et al.*, 2014).
57 Just a few clones can successfully establish themselves in these tissues and disseminate
58 systemically (Meynell, 1957, Lim *et al.*, 2014). Within host tissues, *Salmonella* resides and
59 proliferates predominantly in tissue macrophages but also other cell types (Burton *et al.*,
60 2014). Spleen and liver are major target organs but other tissues are also infected. From the
61 liver, *Salmonella* can reach the gallbladder where they proliferate in gallbladder epithelial
62 cells (and on gallstones, if present). Infected cells activate the inflammasome and are
63 extruded (Knodler *et al.*, 2010). Released *Salmonella* then reach together with bile the
64 intestine and ultimately feces, thus closing the transmission cycle.

65 Taken together, intracellular *Salmonella* proliferation occurs during both diarrheal and
66 systemic disease. The metabolic conditions and mechanisms that drive this intracellular
67 growth are the focus of extensive research efforts since a better overview of the *Salmonella*-
68 host metabolic landscape might open new windows for antimicrobial development. In this
69 review, we discuss some aspects of this exciting field. Additional aspects are covered in other
70 informative recent reviews (Eisenreich *et al.*, 2010, Dandekar *et al.*, 2012, Eisenreich *et*

71 *al.*, 2013, Dandekar *et al.*, 2014, Eisenreich *et al.*, 2015). For *Salmonella* metabolism during
72 extracellular stages, an excellent review has recently been published (Rivera-Chavez *et al.*,
73 2015).

74

75 **Metabolism as a basis for *Salmonella* fitness, virulence, and persistence**

76 *Salmonella* in vivo proliferation requires de novo synthesis of biomass components such as
77 proteins, carbohydrates, lipids and nucleic acids from small molecule precursors. *Salmonella*
78 can obtain these precursors from internal storage such as glycogen or lipids (for a limited
79 number of divisions) or directly from the host microenvironment (e.g., amino acids), and/or
80 synthesize them from a few basic host carbon (such as acetate, glycerol, glucose), nitrogen
81 (e.g., ammonium), sulfur (e.g., sulfate), and phosphor (e.g., phosphate) sources. How
82 *Salmonella* salvages these nutrients from the host is still a matter of debate and will be
83 discussed later on. Nutrient uptake and conversion into biomass requires substantial energy,
84 and finding and exploiting a suitable energy source is the single most important metabolic
85 activity of growing cells (Abu Kwaik *et al.*, 2015). Counterintuitively, *Salmonella* seems to
86 diminish ATP production under some host conditions by direct inhibition of the ATP
87 synthase with MgtC (Lee *et al.*, 2013), a protein that is required for wild-type level
88 *Salmonella* fitness (Alix *et al.*, 2008). This could be a special adaptation to limiting
89 magnesium availability by releasing ATP-bound magnesium for ribosome stabilization
90 (Pontes *et al.*, 2016).

91 Nutrient availability and *Salmonella* metabolic capabilities will modulate overall
92 biomass generation and proliferation (Monahan *et al.*, 2016) and thus *Salmonella* fitness in
93 host tissues during infection. Identifying and quantifying relevant nutrients as well as the
94 corresponding catabolic and anabolic *Salmonella* pathways is therefore of fundamental

95 importance for understanding the disease process and to identify opportunities for specific
96 enzyme inhibitors as urgently needed novel antimicrobials to control infection. Moreover,
97 *Salmonella* metabolic mutants might be useful as live attenuated vaccines (Tennant *et al.*,
98 2015), or as cancer therapeutics (Wang *et al.*, 2016).

99 It is important to note that fitness (the capability to produce viable offspring) does not
100 always correlate with virulence (the capability to cause host pathology). Indeed, *Salmonella*
101 mutants with severe fitness defects nevertheless still cause wild-type level gut pathology in
102 single-strain infections in the mouse enteritis model (Winter *et al.*, 2010, Thiennimitr *et al.*,
103 2011, Faber *et al.*, 2017). Inhibiting the corresponding enzymes would thus have limited
104 impact on disease progression. By contrast, several metabolic mutations (*galE*, *purA*, *aroA*,
105 *aroCD*, *manA*, etc.) abrogate both *Salmonella* in vivo fitness as well as systemic virulence in
106 the mouse typhoid fever model and in human volunteers (Bumann *et al.*, 2000), highlighting
107 metabolism as a key targetable aspect of systemic salmonellosis.

108 Metabolism is not only required for proliferation but also for maintaining essential
109 basal activities even in non-dividing *Salmonella* cells. Identification of such “dormancy”-
110 associated metabolic activities could provide a basis for specific targeting of *Salmonella*
111 persisters that can survive even prolonged antimicrobial chemotherapy (Harms *et al.*, 2016).
112 However, such pathways seem to be quite rare with the possible exception of fatty acid
113 biosynthesis (Barat *et al.*, 2012).

114 Finally, *Salmonella* metabolic enzymes might be important for disease progression
115 not because of their catalytic activity, but rather due to unrelated so-called moonlighting
116 functions (Henderson, 2014). So far, there is only one example of such a moonlighting
117 enzyme with a role in *Salmonella* virulence (the sugar transport protein and metabolic
118 regulator EIIA^{Glc} that activates the second type 3 secretion system encoded on *Salmonella*

119 pathogenicity island 2, (Maze *et al.*, 2014). It is possible that additional enzymes have
120 relevant moonlighting functions as is the case for other pathogens (Henderson, 2014), and
121 this is an important caveat for “simple” metabolic interpretations of enzyme defect
122 phenotypes.

123

124 **Goals for studying intracellular *Salmonella* metabolism**

125 One of the major challenges in studying *Salmonella* in vivo metabolism and identifying
126 potential antimicrobial targets is the strong interplay between *Salmonella* and the mammalian
127 host cells, which provide a very complex metabolic microenvironment for intracellular
128 *Salmonella*. These host cells contain thousands of different metabolites and use versatile
129 regulatory mechanisms to modulate metabolite concentrations and metabolic fluxes.
130 Furthermore, they can dramatically alter their metabolism in various cell differentiation and
131 activation states which strongly influences nutrient availability and hence *Salmonella* fitness.
132 The interplay works in both directions, with the host cell providing nutrients for *Salmonella*,
133 and *Salmonella* simultaneously perturbing the host metabolic network by consuming certain
134 metabolites and releasing waste products (Olive *et al.*, 2016).

135 In addition to these direct interactions, *Salmonella* releases waste products, produces
136 stimulatory components such as lipopolysaccharide, and secretes numerous virulence factors
137 directly into the host cell cytosol. These *Salmonella* activities modulate host cell physiology
138 in a wide variety of aspects including host cell synthesis of toxic molecules that affect
139 *Salmonella* metabolism. This includes nitric oxide, which can block respiration (Husain *et al.*,
140 2008); itaconic acid, which inhibits the glyoxylate shunt (Michelucci *et al.*, 2013); and
141 superoxide/peroxide that damages several bacterial components whose repair requires
142 supportive metabolism (Slauch, 2011, Burton *et al.*, 2014). Importantly, many of these host /

143 *Salmonella* interactions are highly heterogeneous with strong cell-to-cell variation on both
144 the host cell and the *Salmonella* side (Helaine *et al.*, 2014b, Bumann, 2015, Knodler, 2015,
145 Kreibich *et al.*, 2015, Mills *et al.*, 2017, Saliba *et al.*, 2017).

146 To understand how this complex and changing metabolic landscape supports and/or
147 limits *Salmonella* fitness, we need to address the following questions: (i) which nutrients are
148 available for intracellular *Salmonella*, and which host cell supply routes ensure sufficient
149 replacement of consumed nutrients? (ii) which pathways do *Salmonella* employ to utilize
150 these nutrients for energy production and biomass generation, and to what extent can
151 *Salmonella* compensate for perturbations of these processes by employing alternative,
152 partially redundant pathways? (iii) what are the consequences for host cell physiology and
153 metabolism? (iv) what is the level of heterogeneity in host and *Salmonella* metabolism, and
154 are there particularly important subsets with unusual properties?

155

156 **Methods for investigating intracellular *Salmonella* metabolism**

157 The most direct experimental technique to monitor host and *Salmonella* metabolism is
158 metabolomics, which can reveal both metabolite concentrations and metabolic fluxes
159 (Zampieri *et al.*, 2017). Infected cells contain both host and *Salmonella* metabolites, and
160 available separation techniques are too slow compared to the turnover rates for most
161 metabolites, making assignment difficult (except for a few kingdom-specific metabolites such
162 as peptidoglycan and lipid precursors, and secondary metabolites). Mass imaging techniques
163 might offer a solution, but spatial resolution is still insufficient for distinguishing intracellular
164 *Salmonella* from surrounding host cell contents (Petras *et al.*, 2017).

165 Even if we could determine metabolite concentrations in *Salmonella* and their
166 microenvironment, such data would not necessarily reflect their relative importance.

167 Nutrients might be present at low concentration but still have high turnover rates with
168 vigorous *Salmonella* salvage and rapid host replenishment, resulting in an important
169 contribution to *Salmonella* fitness. Instead of metabolite concentrations, metabolic fluxes are
170 therefore more relevant. To obtain such data, one can follow the fate of isotope-labelled
171 glucose and the incorporation of each atom into various amino acids (that are stably retained
172 as part of proteins) (Sauer, 2006, Eisenreich *et al.*, 2015). Amino acid labeling patterns reflect
173 their origin at various central carbon metabolism intermediates, enabling the reconstruction of
174 major fluxes in these central pathways. Interpretation of results for intracellular *Salmonella*
175 can be complicated due to direct transfer of labeled host amino acids into *Salmonella* (Gotz *et*
176 *al.*, 2010). Such approaches mostly focus on incorporation of ¹³C and/or ¹⁵N isotope labels
177 into *Salmonella* biomass. In addition, it can be useful to detect waste products generated by
178 fundamentally important energy conversion pathways in the cell culture medium (Kentner *et*
179 *al.*, 2014, Garcia-Gutierrez *et al.*, 2016). All these techniques might be also applicable for in
180 vivo analysis as *Salmonella* can be purified from infected host tissues using flow cytometry
181 (Becker *et al.*, 2006, Steeb *et al.*, 2013). Data interpretation will need to take into account the
182 increased complexity of whole organism metabolism of labeled nutrients. An exciting recent
183 study tracked incorporation of deuterium-labelled drinking water of *Leishmania*-infected
184 mice into macromolecules of the parasites (Kloehn *et al.*, 2015).

185 Complementary information can be obtained from enzyme proteomics. A general
186 finding from various studies has been the large number and high expression levels of many
187 metabolic enzymes indicating substantial *Salmonella* resource allocation into metabolism.
188 Absolute quantification yields enzyme copy numbers per *Salmonella* cell (Steeb *et al.*, 2013).
189 Combination with tabulated turnover numbers k_{cat} yields maximal reaction rates v_{max} for
190 hundreds of metabolic conversions providing large-scale information on feasible metabolic
191 pathways activities (Steeb *et al.*, 2013, Schubert *et al.*, 2015). Interpretation of such data is,

192 however, complicated by the fact that many enzymes have broader substrate spectrum
193 besides their normally considered specificities (“substrate promiscuity”, e.g., pentoses in
194 addition to hexoses) (Khersonsky *et al.*, 2010). In some cases, such secondary reactions
195 might be actually more relevant. Furthermore, a substantial fraction of metabolic reactions is
196 non-enzymatic, and protein data thus can offer only incomplete coverage of metabolic
197 networks (Keller *et al.*, 2015).

198 An additional layer of complexity is provided by the observation that the majority of
199 metabolic reactions are dispensable for *Salmonella* fitness, since alternative pathways and
200 supplementation by host metabolites often provide partial redundancy, or pathway products
201 are not required (Becker *et al.*, 2006, Bumann, 2009, Steeb *et al.*, 2013). Several genome-
202 scale genetic screens and numerous more focused studies have revealed a few metabolic
203 mutations with severe phenotypes. This may indicate true pathway relevance, or artefacts
204 such as toxicity of truncated gene products, polar effects on downstream genes, or in
205 particular accumulation of toxic upstream intermediates. Such artefacts can be minimized by
206 clean deletion of genes encoding enzymes at metabolism branching points that lead into the
207 pathway of interest (“first committed step”), with other branches buffering potential buildup
208 of toxic precursors. Access to essential biomass precursors can be inferred from auxotrophic
209 strains that depend on external supplementation. Interpretation should consider wasteful
210 *Salmonella* degradation of such precursors (e.g. dispensable *Salmonella* lysine decarboxylase,
211 which lowers lysine availability below biomass needs (Steeb *et al.*, 2013)). Another
212 complication could be moonlighting functions (see above). Single mutants can only identify
213 non-redundant pathways. To determine the relevance of much more frequent partially
214 redundant pathways, multiple mutations must be combined, and epistasis can provide further
215 insights into pathway architecture (Ideker *et al.*, 2012).

216 Understanding the metabolism network underlying *Salmonella* fitness during
217 infection requires genome-scale integration of all complementary data sets. The consensus in
218 silico reconstruction of *Salmonella* metabolism that was obtained in a jamboree involving
219 more than fifty researchers provides a suitable basis for this (Thiele *et al.*, 2011). It accounts
220 for 1270 metabolic genes, 2201 metabolic reactions that were curated for thermodynamically
221 feasible reversibility, and 1110 metabolites. This reconstruction reveals all known metabolic
222 pathways and their interconnectivity as a basis for studying the entire *Salmonella* metabolism
223 network in different external conditions and internal states.

224 The substantial progress in understanding intracellular *Salmonella* metabolism is
225 encouraging but one crucial, previously neglected aspect is just emerging. All experimental
226 and in silico methods are based on population averages, but recent work has shown extensive
227 heterogeneity between infected host cells and individual *Salmonella* cells in terms of
228 microenvironments, stress, gene expression, overall metabolic activities, growth rates, and
229 cell fates (Helaine *et al.*, 2014b, Bumann, 2015, Knodler, 2015, Kreibich *et al.*, 2015, Mills *et*
230 *al.*, 2017, Saliba *et al.*, 2017). Differential nutrient access seems to cause heterogeneous
231 *Salmonella* growth rates during systemic infection in vivo, with important consequences for
232 disease progression and tolerance against antimicrobial chemotherapy (Claudi *et al.*, 2014).
233 New approaches for *Salmonella* single-cell and subpopulation analysis will be needed to
234 unravel this fascinating new aspect of host-*Salmonella* interactions.

235

236 **Metabolic patterns of intracellular *Salmonella* in in vitro cell culture models**

237 *Salmonella* metabolism in cell culture infections has been covered in excellent recent reviews
238 (Dandekar *et al.*, 2014, Eisenreich *et al.*, 2015), and we just summarize some findings here.
239 Cell culture infections recapitulate a central hallmark of salmonellosis, intracellular

240 *Salmonella* replication in host cells. Compared to in vivo studies, cell culture infections
241 enable detailed experimental analysis with a broad spectrum of techniques. Cell culture
242 conditions such as medium composition and oxygen tension can be freely adjusted according
243 to the specific research questions, and defined pulses of isotopically labeled nutrients enable
244 tracking of the kinetics of metabolite conversion in both host and *Salmonella* cells. Another
245 advantage is the focus on a single host cell type simplifying analysis and interpretation of
246 results compared to complex in vivo situations.

247 The results obtained so far indicate a major role of glucose as carbon/energy source,
248 under some, but not all experimental conditions (Bowden *et al.*, 2009, Holzer *et al.*, 2012,
249 Steeb *et al.*, 2013, Bowden *et al.*, 2014, Dandekar *et al.*, 2014, Eisenreich *et al.*, 2015, Popp
250 *et al.*, 2015, Garcia-Gutierrez *et al.*, 2016, Liu *et al.*, 2017, Singh *et al.*, 2017). Peptides/
251 amino acids (Popp *et al.*, 2015, Singh *et al.*, 2017) and other nutrients such as C3 (pyruvate
252 and/or glycerol) or C2 (acetate and/or fatty acids) metabolites (Gotz *et al.*, 2010) are also
253 available to intracellular *Salmonella*. *Salmonella* degrades these nutrients with its central
254 carbon metabolism pathways such as glycolysis (Bowden *et al.*, 2014, Garcia-Gutierrez *et al.*,
255 2016) and the TCA cycle (Bowden *et al.*, 2010), and uses various intermediates of these
256 pathways to synthesize several amino acids in addition to amino acids obtained from the host
257 cell (Gotz *et al.*, 2010). However, results have been quite diverse depending on specific host
258 cells and conditions (Fig. 1A). Clarification of the most relevant setting should be a priority
259 of future work (see below).

260 *Salmonella* can also directly modulate host amino acid abundance. *Salmonella*
261 catabolism of host asparagine causes T cell suppression in vitro, but has no detectable impact
262 in vivo (Kullas *et al.*, 2012), suggesting other reasons for fitness contributions of *Salmonella*
263 asparagine catabolism (Jelsbak *et al.*, 2014). *Salmonella* induces host arginase II expression
264 (Lahiri *et al.*, 2008), in addition to “stealing” of host arginine by ArgT-mediated uptake (Das

265 *et al.*, 2010). Both processes could deprive host cells of a precursor for generating
266 antimicrobial nitric oxide, but *Salmonella* subsets experience substantial nitric oxide levels
267 during infection (Burton *et al.*, 2014) suggesting sufficient arginine availability. Moreover,
268 *Salmonella* arginine deiminase contributes to in vivo fitness without affecting host nitric
269 oxide production (Choi *et al.*, 2012), and arginine seems to serve as *Salmonella*
270 carbon/nitrogen source (Steeb *et al.*, 2013). *Salmonella* also induces host tryptophan
271 catabolites with immunomodulatory properties in the bloodstream of humans and mice
272 (Blohmke *et al.*, 2016).

273 One major question is how the host supplies nutrients for intracellular *Salmonella*
274 (Fig. 1B). One fascinating mechanism could be the formation of a large membrane network
275 called *Salmonella*-induce filaments (Sif) (Liss *et al.*, 2017). *Salmonella* can induce Sif with
276 effector proteins that it injects into the host cell cytosol using the type 3 secretion system
277 encoded on *Salmonella* pathogenicity island 2 (SPI-2). Sif continuously merge with
278 endosomes providing a gateway between extracellular metabolites, which the host cell takes
279 up by pinocytosis, and the *Salmonella*-containing vacuole (Drecktrah *et al.*, 2007, Liss *et al.*,
280 2017). Indeed, this can be the major nutrient delivery pipeline for driving intracellular
281 *Salmonella* growth (Holzer *et al.*, 2012, Liss *et al.*, 2017). An additional host cell nutrient
282 supply pathway is chaperone-mediated autophagy providing peptides directly to the
283 *Salmonella*-containing vacuole (Singh *et al.*, 2017), which works independently of any
284 extracellular nutrient supply.

285

286 **Future goals for in vitro cell culture studies**

287 An important goal is to define meaningful criteria for in vitro cell culture conditions that
288 reproduce key aspects of host-*Salmonella* interactions during salmonellosis. Recent studies

289 have revealed dramatic differences in *Salmonella* metabolism and virulence mechanisms
290 depending on particular host cell types and experimental conditions, and it remains often
291 unclear which patterns are most pertinent for understanding actual disease processes.

292 Most studies used cancer cell lines that are easy to cultivate and grow, and are
293 permissive for *Salmonella* proliferation. However, compared to primary cells these cancer
294 cells have distorted metabolism (respiration/fermentation, pentose pathway, lipid
295 biosynthesis/ β -oxidation, etc.) (Pavlova *et al.*, 2016), which might affect the metabolism of
296 intracellular *Salmonella*. The major model for epithelial cell infections are HeLa cells that are
297 cervix carcinoma cells carrying the Human Papilloma virus 18 genome. *Salmonella* infection
298 biology in HeLa cells differs in important aspects from (possibly more relevant) polarized
299 epithelial cells, even when compared under identical conditions (Fig. 1A). This includes
300 differential overall growth rates; relevance of glucose and other nutrients; divergent roles of
301 glycolysis, overflow metabolism leading to acetate secretion, purine biosynthesis, chorismate
302 biosynthesis (a key pathway for classifying biosafety of *Salmonella* mutants); and
303 essentiality/dispensability of Sif formation (Holzer *et al.*, 2012, Bowden *et al.*, 2014,
304 Lorkowski *et al.*, 2014, Popp *et al.*, 2015, Garcia-Gutierrez *et al.*, 2016, Liu *et al.*, 2017,
305 Singh *et al.*, 2017).

306 Similarly, *Salmonella* metabolism and virulence mechanisms show remarkable
307 differences depending on the macrophage activation status and source of host cells (cancer
308 cell lines, primary bone marrow-derived macrophages) (Fig. 1A). Examples include the
309 differential relevance of glucose for *Salmonella* nutrition; divergent roles of *Salmonella* TCA
310 cycle and overflow metabolism; and differential requirements for Sif (Bowden *et al.*, 2009,
311 Lathrop *et al.*, 2015, Popp *et al.*, 2015, Garcia-Gutierrez *et al.*, 2016) and extracellular small
312 metabolites that could be supplied via Sif (Singh *et al.*, 2017). Interestingly, one study
313 suggested that SPI-2 and its role in Sif formation are actually dispensable for intracellular

314 growth in phagocytes in vivo. Instead, SPI-2 seems to play a major role in *Salmonella* cell-to-
315 cell spreading within host tissues (Grant *et al.*, 2012), which is not the focus of most in vitro
316 cell culture studies although it is an essential part of *Salmonella* in vivo fitness. Another
317 particularly concerning discrepancy is the apparent dispensability of *Salmonella* respiration
318 for growth in macrophages in vitro (Garcia-Gutierrez *et al.*, 2016), whereas aerobic
319 respiration is one of the key metabolic activities supporting *Salmonella* fitness in vivo
320 (Turner *et al.*, 2003, Steeb *et al.*, 2013).

321 Another caveat concerning in vitro *Salmonella* studies is the common use of cell
322 culture media that contain non-physiological metabolite concentrations, which might affect
323 both host cell and intracellular *Salmonella* metabolism. Intestinal epithelial cells (enterocytes)
324 that are one important infected host cell type in vivo, do for example not normally depend on
325 glucose but rather on microbiota-derived short-chain fatty acids as energy source although
326 this can change during gut dysbiosis (Rivera-Chavez *et al.*, 2016).

327 To deal with this complexity and to ensure that the results are meaningful for
328 understanding disease mechanisms in salmonellosis, we propose to derive a couple of
329 decisive benchmarks from in vivo studies, and to use these benchmarks for establishment of
330 appropriate in vitro cell culture models. As an example, *Salmonella* fitness in macrophage
331 cell cultures should depend on respiratory pathways as it does in vivo. Glucose should
332 contribute as a carbon and energy source, but only as one limited contribution among several
333 nutrients (Bowden *et al.*, 2009, Steeb *et al.*, 2013) (whereas it could be more relevant during
334 chronic infections (Eisele *et al.*, 2013)). Benchmarks for metabolic pathways relevant for
335 *Salmonella* fitness in epithelial cells in vivo are still largely lacking, but their establishment
336 could be straightforward with *Salmonella* mutants in the mouse enteritis and/or neonate
337 infection models. In particular, the role of central metabolic pathways and host cell processes
338 such as Sif formation or chaperone-activated autophagy should be clarified in vivo. Once

339 such criteria are established, host cell types and culture conditions could be optimized in an
340 iterative manner until key aspects of *Salmonella* intracellular metabolism in vivo are
341 faithfully reproduced in vitro. A final step could be to reproduce the intracellular
342 environment, and *Salmonella* exploitation of accessible nutrients as well as defense against
343 toxic molecules, in axenic cultures (without any host cell). This would be particularly useful
344 for screening of novel antimicrobials under meaningful conditions.

345 A second focus of future studies of *Salmonella* in vitro cell culture infection models
346 should be on heterogeneity. Most previous investigations have determined average properties,
347 but recent studies clearly revealed striking differences between individual *Salmonella* cells
348 but also substantial cell-to-cell variation among host cells. *Salmonella* subsets with divergent
349 growth rates and metabolic activities exist in infected macrophages (Helaine *et al.*, 2010,
350 Claudi *et al.*, 2014, Helaine *et al.*, 2014a, Diacovich *et al.*, 2016), and properties and fates of
351 individual *Salmonella*-infected macrophages also highly variable (Avraham *et al.*, 2015,
352 Saliba *et al.*, 2016, Thurston *et al.*, 2016, McQuate *et al.*, 2017). Striking heterogeneity has
353 also been observed in epithelial HeLa cells. Most *Salmonella* remain initially in phagosomes
354 where they slowly proliferate, but some *Salmonella* escape to the host cell cytosol where they
355 can vigorously proliferate and overgrow the phagosomal *Salmonella* subpopulation, (Knodler
356 *et al.*, 2010, Knodler, 2015). While their differential growth rates must correspond to striking
357 differences in biomass generation and the entire metabolism network (Knodler *et al.*, 2010,
358 Knodler, 2015, Wrande *et al.*, 2016), and recent evidence reveals distinct gene expression
359 patterns and genetic determinants for the two subpopulations (Knodler *et al.*, 2010, Knodler,
360 2015, Wrande *et al.*, 2016), most HeLa infection studies merely determined average
361 properties. Such data initially reflect mostly phagosomal *Salmonella*, but later predominantly
362 the overgrowing cytosolic *Salmonella* subset. Consequently, data for early time points largely
363 ignore the properties of a nevertheless particularly important *Salmonella* subset (the cytosolic

364 escapers), and differences along the time course could be misinterpreted as changing
365 metabolic patterns of *Salmonella* cells, instead of changing contributions of two distinct
366 subsets. It is possible that cytosolic *Salmonella* resemble cytosolic *Shigella*, which rely on
367 conversion of host-derived pyruvate to acetate as the major energy conversion pathway
368 (Kentner *et al.*, 2014). In particular, *Salmonella* can grow even without glycolysis in these
369 cells, excretes large amounts of acetate, and partially depends on acetyl-CoA to acetate
370 conversion (Bowden *et al.*, 2014, Garcia-Gutierrez *et al.*, 2016, Liu *et al.*, 2017).

371 Traditional bulk average read-outs neglect this heterogeneity and could thus result in
372 misleading interpretations. Single-cell approaches increasingly unravel the molecular
373 differences between *Salmonella* and host cell subsets, but the corresponding metabolic
374 patterns are still largely unknown.

375

376 ***Salmonella* metabolism during systemic infections**

377 In vivo models reflect relevant conditions during salmonellosis compared to more ambiguous
378 cell culture conditions. For practical reasons most studies used a typhoid fever model of
379 systemic salmonellosis in genetically susceptible mice. This model differs in some important
380 aspects from human systemic salmonellosis (Santos *et al.*, 2001), but the limited available
381 information suggests at least similarities in *Salmonella* metabolism as compared to
382 genetically resistant mice (Steeb *et al.*, 2013) and human volunteers immunized with
383 attenuated *Salmonella enterica* serovar Typhi (Bumann *et al.*, 2000). A major drawback of in
384 vivo studies is the severely restricted number of suitable experimental methods for
385 investigating metabolism, and the much higher complexity of the host microenvironment
386 with multiple cell types and strong inflammation dynamics. Under these circumstances, there
387 are at present essentially only two applicable methods to study *Salmonella* metabolism;

388 proteomics to determine enzyme copy numbers, and competitive infections to determine
389 fitness defects of metabolic mutants. On the other hand, contributions of many research
390 groups over more than three decades have accumulated an astonishing amount of information
391 that enabled us to derive a genome-scale metabolic reconstruction of *Salmonella* metabolism
392 in infected mouse spleen (Steeb *et al.*, 2013) (Fig. 2). Subsequent publications corrected
393 some aspects (hydrogen oxidation not required (Maier *et al.*, 2013, Maier *et al.*, 2014);
394 reconsideration of proline biosynthesis mutants for inferring limited proline availability (Lee
395 *et al.*, 2014); contribution of asparagine deamination and polyamine synthesis for *Salmonella*
396 fitness (Jelsbak *et al.*, 2014)). However, this did not have much impact on the overall
397 properties of the *Salmonella* metabolism network in vivo.

398 One striking finding is the large complexity of the in vivo host-*Salmonella* nutritional
399 interface (Fig. 2). *Salmonella* has access to more than fifty diverse host nutrients comprising
400 multiple carbon/energy and nitrogen sources, all amino acids (with limiting amounts for
401 proline), many provitamins, and inorganic nutrients. Although an individual nutrient,
402 glycerol, plays a key role, the broad availability of many different nutrients makes
403 *Salmonella* metabolism largely resilient against perturbations. This in part explains the
404 seemingly paradoxical finding that *Salmonella* invests major resources into metabolic
405 enzymes suggesting a crucial importance of metabolism for *Salmonella* fitness in vivo, yet
406 only few metabolic mutations show remarkable infection phenotypes (Becker *et al.*, 2006,
407 Bumann, 2009, Steeb *et al.*, 2013). Many other microbial pathogens likely have access to
408 similar complex host nutrients based on widespread auxotrophies for amino acids,
409 nucleosides, and (pro)vitamins (Steeb *et al.*, 2013).

410 *Salmonella* degrades many of these nutrients primarily through the Embden-Meyerhof
411 pathway (and to some extent also pentose-phosphate and Entner-Doudoroff), followed by the
412 TCA cycle coupled with aerobic respiration involving ubiquinone as the main energy

413 providing pathway. Anaerobic respiration is dispensable (Craig *et al.*, 2013) although
414 *Salmonella* expresses several enzymes that could mediate such energy conversion pathways
415 in vivo (Steeb *et al.*, 2013). Vulnerable “Achilles heels” are rare in *Salmonella* metabolism
416 and are almost entirely restricted to biosynthesis of essential biomass components that are not
417 provided in sufficient amounts, or not at all, by the host such as peptidoglycan, riboflavin,
418 unsaturated fatty acids, ubiquinone, etc. (Becker *et al.*, 2006, Bumann, 2009, Steeb *et al.*,
419 2013).

420 As discussed above, *Salmonella* has access to a wide variety of different host-
421 nutrients. However, this does not necessary imply favorable conditions as available amounts
422 could be still scarce. Quantitative simulation of the entire *Salmonella* metabolic network
423 based on all available experimental data indeed suggested a severe overall nutrient limitation
424 of *Salmonella* growth, suggesting that although the host microenvironment is qualitatively
425 rich (providing many different nutrients), it is quantitatively poor (nutrients are available in
426 only scarce amounts) resulting in slow growth with an average generation time around 6 h
427 (Becker *et al.*, 2006, Claudi *et al.*, 2014).

428 *Salmonella* metabolism does not only depend on nutrient access. Host cells can also
429 attack *Salmonella* with toxic molecules such as nitric oxide and reactive oxygen species
430 (ROS), that could interfere with *Salmonella* metabolism and consume reducing equivalents
431 for detoxification and repair. Nitric oxide can block *Salmonella* respiration (Husain *et al.*,
432 2008), but exposed *Salmonella* upregulate the detoxifying enzyme NO dioxygenase HmpA
433 which lowers nitric oxide levels sufficiently to prevent fitness defects (Burton *et al.*, 2014).
434 Similarly, *Salmonella* that are exposed to moderate levels of reactive oxygen species in
435 resident macrophages, upregulate catalases and peroxidases that together with generally
436 expressed superoxide dismutase ensure uncompromised fitness (Burton *et al.*, 2014). By
437 contrast, neutrophils attack *Salmonella* with much higher levels of ROS that overwhelm

438 *Salmonella* defenses (Burton *et al.*, 2014, Schurmann *et al.*, 2017). Both *Salmonella* defenses
439 against nitric oxide and ROS require reducing equivalents but this puts only small additional
440 demands on *Salmonella* metabolism (in the range of 10% of total electron flow). Activated
441 macrophages also express cis-aconitate decarboxylase (Irg1) (Michelucci *et al.*, 2013), which
442 produces itaconate. Itaconate could inhibit the *Salmonella* glyoxylate shunt, but
443 concentrations are probably too low for fitness impairment, especially since *Salmonella* does
444 not depend on the glyoxylate shunt during acute infections (Fang *et al.*, 2005, Kim *et al.*,
445 2006). On the other hand, itaconate also inhibits host succinate dehydrogenase resulting in
446 succinate accumulation, which increases inflammatory responses (Cordes *et al.*, 2016) and
447 modulates host fatty acid metabolism and ROS production (Hall *et al.*, 2013).

448 As might be expected from the striking variation among both *Salmonella* and infected
449 host cells in vitro (see above), *Salmonella* growth and metabolism is also highly
450 heterogeneous in vivo (Claudi *et al.*, 2014, Helaine *et al.*, 2014a, Bumann, 2015). This is in
451 part a consequence of differential stress conditions and *Salmonella* toxin expression, but
452 varying access to host nutrients and inhomogeneous activities across the entire *Salmonella*
453 metabolism network are also involved. The individual relevance of the many metabolic
454 difference is still largely unclear, but growth patterns of a purine auxotrophic mutant indicate
455 divergent *Salmonella* access to purines in vivo. Interestingly, nutrient access seems to be
456 rather homogeneous within one *Salmonella* microcolony in one host cell, but can be very
457 different in neighboring host cells suggesting that host cell properties might modulate nutrient
458 supply (Claudi *et al.*, 2014).

459

460 **Future goals for in vivo studies**

461 A better understanding of heterogeneous *Salmonella* metabolism is clearly required to
462 unravel host and *Salmonella* molecular mechanisms that enable rapid growth of some
463 *Salmonella* subsets driving disease progression, but cause only slow to moderate growth of
464 other subsets which enables these *Salmonella* cells to tolerate antibiotics exposure (Claudi *et*
465 *al.*, 2014). New single-cell techniques will be required to characterize qualitative and
466 quantitative differences in nutrient access and metabolic pathway activities in the various
467 *Salmonella* subsets. Apart from growth rate, other aspects of metabolism could also influence
468 antimicrobial susceptibility and tolerance, and this could be highly relevant for explaining the
469 surprisingly slow *Salmonella* eradication from infected mice and humans (Waddington *et al.*,
470 2014, Dobinson *et al.*, 2017) with antibiotics that are highly effective against *Salmonella* in
471 vitro.

472 Finally, a major enigma is still the mechanism of host nutrient delivery to intracellular
473 *Salmonella*. Elegant in vitro studies suggest a major role in SPI-2 inducing Sif that connect
474 the extracellular fluid to the *Salmonella*-containing vacuole (Liss *et al.*, 2017). However,
475 nutrients that actually reach *Salmonella* in vivo do not show a typical signature of blood
476 metabolites but rather suggest predominant nutrient release by degradation of host
477 macromolecules (Steeb *et al.*, 2013), as would occur in lysosomes or autophagosomes.
478 Moreover, one study challenges the role of SPI-2 (and therefore Sif) for intracellular
479 *Salmonella* growth in vivo (Grant *et al.*, 2012). Further work might (i) determine the in vivo
480 occurrence of Sif around *Salmonella*-containing vacuoles in macrophages, (ii) determine
481 nutrient access in *Salmonella* wild-type and SPI-2 mutants, and (iii) clarify the importance of
482 vesicular trafficking and alternative mechanisms for nutrient delivery to the *Salmonella*-
483 containing vacuoles. Another very recent study proposes that host cell chaperone-mediated
484 autophagy provides peptides (and possibly other host macromolecule degradation products)
485 directly to the *Salmonella*-containing vacuole (Singh *et al.*, 2017). Although this supply route

486 appears to have limited relevance for fitness of wild-type *Salmonella* in vitro cell culture
487 infections (in contrast to a peptide-dependent mutant), this mechanism might still play a role
488 in vivo. Methods that have been established to purify and analyze the phagosomal membrane
489 from in vitro infected cells (Herweg *et al.*, 2015, Vorwerk *et al.*, 2015), might be applicable
490 to in vivo conditions to obtain informative comprehensive data on suitable marker proteins
491 (in addition to immunohistochemistry data) to address these issues.

492

493 **Acknowledgments**

494 We thank past and present lab members for their contributions and Max-Planck-Gesellschaft,
495 Deutsche Forschungsgemeinschaft, Schweizerischer Nationalfonds, and SystemsX.ch for
496 funding our work on pathogen metabolism. We declare to have no conflicts of interest.

497

498 **References**

499

- 500 Abu Kwaik, Y. and Bumann, D. (2015). Host Delivery of Favorite Meals for Intracellular Pathogens.
501 *PLoS Pathog* **11**, e1004866.
- 502 Alix, E., Miki, T., Felix, C., Rang, C., Figueroa-Bossi, N., Demettre, E. and Blanc-Potard, A.B. (2008).
503 Interplay between MgtC and PagC in Salmonella enterica serovar Typhimurium. *Microb*
504 *Pathog* **45**, 236-240.
- 505 Avraham, R., Haseley, N., Brown, D., Penaranda, C., Jijon, H.B., Trombetta, J.J., *et al.* (2015).
506 Pathogen Cell-to-Cell Variability Drives Heterogeneity in Host Immune Responses. *Cell* **162**,
507 1309-1321.
- 508 Barat, S., Steeb, B., Maze, A. and Bumann, D. (2012). Extensive in vivo resilience of persistent
509 Salmonella. *PLoS One* **7**, e42007.
- 510 Becker, D., Selbach, M., Rollenhagen, C., Ballmaier, M., Meyer, T.F., Mann, M. and Bumann, D.
511 (2006). Robust Salmonella metabolism limits possibilities for new antimicrobials. *Nature*.
512 **440**, 303-307.
- 513 Blohmke, C.J., Darton, T.C., Jones, C., Suarez, N.M., Waddington, C.S., Angus, B., *et al.* (2016).
514 Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of
515 typhoid fever. *J Exp Med* **213**, 1061-1077.
- 516 Bowden, S.D., Hopper-Chidlaw, A.C., Rice, C.J., Ramachandran, V.K., Kelly, D.J. and Thompson, A.
517 (2014). Nutritional and metabolic requirements for the infection of HeLa cells by Salmonella
518 enterica serovar Typhimurium. *PLoS One* **9**, e96266.
- 519 Bowden, S.D., Ramachandran, V.K., Knudsen, G.M., Hinton, J.C. and Thompson, A. (2010). An
520 incomplete TCA cycle increases survival of Salmonella Typhimurium during infection of
521 resting and activated murine macrophages. *PLoS One* **5**, e13871.
- 522 Bowden, S.D., Rowley, G., Hinton, J.C. and Thompson, A. (2009). Glucose and glycolysis are required
523 for the successful infection of macrophages and mice by Salmonella enterica serovar
524 typhimurium. *Infect Immun* **77**, 3117-3126.
- 525 Bumann, D. (2009). System-level analysis of Salmonella metabolism during infection. *Curr Opin*
526 *Microbiol* **12**, 559-567.
- 527 Bumann, D. (2015). Heterogeneous host-pathogen encounters: act locally, think globally. *Cell host &*
528 *microbe* **17**, 13-19.
- 529 Bumann, D., Hueck, C., Aebischer, T. and Meyer, T.F. (2000). Recombinant live Salmonella spp. for
530 human vaccination against heterologous pathogens. *FEMS Immunol.Med.Microbiol.* **27**, 357-
531 364.
- 532 Burton, N.A., Schurmann, N., Casse, O., Steeb, A.K., Claudi, B., Zankl, J., *et al.* (2014). Disparate
533 impact of oxidative host defenses determines the fate of Salmonella during systemic
534 infection in mice. *Cell host & microbe* **15**, 72-83.
- 535 Choi, Y., Choi, J., Groisman, E.A., Kang, D.H., Shin, D. and Ryu, S. (2012). Expression of STM4467-
536 encoded arginine deiminase controlled by the STM4463 regulator contributes to Salmonella
537 enterica serovar Typhimurium virulence. *Infect Immun* **80**, 4291-4297.
- 538 Claudi, B., Sprote, P., Chirkova, A., Personnic, N., Zankl, J., Schurmann, N., *et al.* (2014). Phenotypic
539 variation of salmonella in host tissues delays eradication by antimicrobial chemotherapy.
540 *Cell* **158**, 722-733.
- 541 Cordes, T., Wallace, M., Michelucci, A., Divakaruni, A.S., Sapcariu, S.C., Sousa, C., *et al.* (2016).
542 Immunoresponsive Gene 1 and Itaconate Inhibit Succinate Dehydrogenase to Modulate
543 Intracellular Succinate Levels. *J Biol Chem* **291**, 14274-14284.

544 Craig, M., Sadik, A.Y., Golubeva, Y.A., Tidhar, A. and Slauch, J.M. (2013). Twin-arginine translocation
545 system (tat) mutants of Salmonella are attenuated due to envelope defects, not respiratory
546 defects. *Mol Microbiol* **89**, 887-902.

547 Dandekar, T., Astrid, F., Jasmin, P. and Hensel, M. (2012). Salmonella enterica: a surprisingly well-
548 adapted intracellular lifestyle. *Front Microbiol* **3**, 164.

549 Dandekar, T., Fieselmann, A., Fischer, E., Popp, J., Hensel, M. and Noster, J. (2014). Salmonella-how a
550 metabolic generalist adopts an intracellular lifestyle during infection. *Frontiers in cellular and*
551 *infection microbiology* **4**, 191.

552 Darwin, K.H. and Miller, V.L. (1999). Molecular basis of the interaction of Salmonella with the
553 intestinal mucosa. *Clinical microbiology reviews* **12**, 405-428.

554 Das, P., Lahiri, A., Lahiri, A., Sen, M., Iyer, N., Kapoor, N., *et al.* (2010). Cationic amino acid
555 transporters and Salmonella Typhimurium ArgT collectively regulate arginine availability
556 towards intracellular Salmonella growth. *PLoS One* **5**, e15466.

557 Diacovich, L., Lorenzi, L., Tomassetti, M., Meresse, S. and Gramajo, H. (2016). The infectious
558 intracellular lifestyle of Salmonella enterica relies on the adaptation to nutritional conditions
559 within the Salmonella-containing vacuole. *Virulence*, 1-18.

560 Dobinson, H.C., Gibani, M.M., Jones, C., Thomaidis-Brears, H.B., Voysey, M., Darton, T.C., *et al.*
561 (2017). Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A
562 Infection in the First Paratyphoid Human Challenge Model. *Clin Infect Dis* **64**, 1066-1073.

563 Drecktrah, D., Knodler, L.A., Howe, D. and Steele-Mortimer, O. (2007). Salmonella trafficking is
564 defined by continuous dynamic interactions with the endolysosomal system. *Traffic* **8**, 212-
565 225.

566 Eisele, N.A., Ruby, T., Jacobson, A., Manzanillo, P.S., Cox, J.S., Lam, L., *et al.* (2013). Salmonella
567 require the fatty acid regulator PPARdelta for the establishment of a metabolic environment
568 essential for long-term persistence. *Cell Host Microbe* **14**, 171-182.

569 Eisenreich, W., Dandekar, T., Heesemann, J. and Goebel, W. (2010). Carbon metabolism of
570 intracellular bacterial pathogens and possible links to virulence. *Nat Rev Microbiol* **8**, 401-
571 412.

572 Eisenreich, W., Heesemann, J., Rudel, T. and Goebel, W. (2013). Metabolic host responses to
573 infection by intracellular bacterial pathogens. *Frontiers in cellular and infection microbiology*
574 **3**, 24.

575 Eisenreich, W., Heesemann, J., Rudel, T. and Goebel, W. (2015). Metabolic Adaptations of
576 Intracellular Bacterial Pathogens and their Mammalian Host Cells during Infection
577 ("Pathometabolism"). *Microbiology spectrum* **3**.

578 Faber, F., Thiennimitr, P., Spiga, L., Byndloss, M.X., Litvak, Y., Lawhon, S., *et al.* (2017). Respiration of
579 Microbiota-Derived 1,2-propanediol Drives Salmonella Expansion during Colitis. *PLoS Pathog*
580 **13**, e1006129.

581 Fang, F.C., Libby, S.J., Castor, M.E. and Fung, A.M. (2005). Isocitrate lyase (AceA) is required for
582 Salmonella persistence but not for acute lethal infection in mice. *Infect.Immun.* **73**, 2547-
583 2549.

584 Garcia-Gutierrez, E., Chidlaw, A.C., Le Gall, G., Bowden, S.D., Tedin, K., Kelly, D.J. and Thompson, A.
585 (2016). A Comparison of the ATP Generating Pathways Used by S. Typhimurium to Fuel
586 Replication within Human and Murine Macrophage and Epithelial Cell Lines. *PLoS One* **11**,
587 e0150687.

588 Gotz, A., Eylert, E., Eisenreich, W. and Goebel, W. (2010). Carbon metabolism of enterobacterial
589 human pathogens growing in epithelial colorectal adenocarcinoma (Caco-2) cells. *PLoS One*
590 **5**, e10586.

591 Grant, A.J., Morgan, F.J., McKinley, T.J., Foster, G.L., Maskell, D.J. and Mastroeni, P. (2012).
592 Attenuated Salmonella Typhimurium lacking the pathogenicity island-2 type 3 secretion
593 system grow to high bacterial numbers inside phagocytes in mice. *PLoS Pathog* **8**, e1003070.

594 Hall, C.J., Boyle, R.H., Astin, J.W., Flores, M.V., Oehlers, S.H., Sanderson, L.E., *et al.* (2013).
595 Immuno-responsive gene 1 augments bactericidal activity of macrophage-lineage cells by
596 regulating beta-oxidation-dependent mitochondrial ROS production. *Cell metabolism* **18**,
597 265-278.

598 Halle, S., Bumann, D., Herbrand, H., Willer, Y., Dahne, S., Forster, R. and Pabst, O. (2007). Solitary
599 intestinal lymphoid tissue provides a productive port of entry for Salmonella enterica
600 serovar Typhimurium. *Infect.Immun.* **75**, 1577-1585.

601 Harms, A., Maisonneuve, E. and Gerdes, K. (2016). Mechanisms of bacterial persistence during stress
602 and antibiotic exposure. *Science* **354**.

603 Havelaar, A.H., Kirk, M.D., Torgerson, P.R., Gibb, H.J., Hald, T., Lake, R.J., *et al.* (2015). World Health
604 Organization Global Estimates and Regional Comparisons of the Burden of Foodborne
605 Disease in 2010. *PLoS Med* **12**, e1001923.

606 Helaine, S., Cheverton, A.M., Watson, K.G., Faure, L.M., Matthews, S.A. and Holden, D.W. (2014a).
607 Internalization of Salmonella by macrophages induces formation of nonreplicating
608 persisters. *Science* **343**, 204-208.

609 Helaine, S. and Kugelberg, E. (2014b). Bacterial persisters: formation, eradication, and experimental
610 systems. *Trends Microbiol* **22**, 417-424.

611 Helaine, S., Thompson, J.A., Watson, K.G., Liu, M., Boyle, C. and Holden, D.W. (2010). Dynamics of
612 intracellular bacterial replication at the single cell level. *Proc Natl Acad Sci U S A* **107**, 3746-
613 3751.

614 Henderson, B. (2014). An overview of protein moonlighting in bacterial infection. *Biochem Soc Trans*
615 **42**, 1720-1727.

616 Herweg, J.A., Hansmeier, N., Otto, A., Geffken, A.C., Subbarayal, P., Prusty, B.K., *et al.* (2015).
617 Purification and proteomics of pathogen-modified vacuoles and membranes. *Frontiers in*
618 *cellular and infection microbiology* **5**, 48.

619 Holzer, S.U. and Hensel, M. (2012). Divergent roles of Salmonella pathogenicity island 2 and
620 metabolic traits during interaction of S. enterica serovar typhimurium with host cells. *PLoS*
621 *One* **7**, e33220.

622 Husain, M., Bourret, T.J., McCollister, B.D., Jones-Carson, J., Laughlin, J. and Vazquez-Torres, A.
623 (2008). Nitric oxide evokes an adaptive response to oxidative stress by arresting respiration.
624 *J Biol Chem* **283**, 7682-7689.

625 Ideker, T. and Krogan, N.J. (2012). Differential network biology. *Mol Syst Biol* **8**, 565.

626 Jelsbak, L., Hartman, H., Schroll, C., Rosenkrantz, J.T., Lemire, S., Wallrodt, I., *et al.* (2014).
627 Identification of metabolic pathways essential for fitness of Salmonella Typhimurium in vivo.
628 *PLoS One* **9**, e101869.

629 Keestra-Gounder, A.M., Tsois, R.M. and Baumler, A.J. (2015). Now you see me, now you don't: the
630 interaction of Salmonella with innate immune receptors. *Nature reviews. Microbiology* **13**,
631 206-216.

632 Keller, M.A., Piedrafita, G. and Ralser, M. (2015). The widespread role of non-enzymatic reactions in
633 cellular metabolism. *Curr Opin Biotechnol* **34**, 153-161.

634 Kentner, D., Martano, G., Callon, M., Chiquet, P., Brodmann, M., Burton, O., *et al.* (2014). Shigella
635 reroutes host cell central metabolism to obtain high-flux nutrient supply for vigorous
636 intracellular growth. *Proceedings of the National Academy of Sciences of the United States of*
637 *America* **111**, 9929-9934.

638 Khersonsky, O. and Tawfik, D.S. (2010). Enzyme promiscuity: a mechanistic and evolutionary
639 perspective. *Annual review of biochemistry* **79**, 471-505.

640 Kim, Y.R., Brinsmade, S.R., Yang, Z., Escalante-Semerena, J. and Fierer, J. (2006). Mutation of
641 phosphotransacetylase but not isocitrate lyase reduces the virulence of Salmonella enterica
642 serovar Typhimurium in mice. *Infect Immun* **74**, 2498-2502.

643 Kloehn, J., Saunders, E.C., O'Callaghan, S., Dagley, M.J. and McConville, M.J. (2015). Characterization
644 of metabolically quiescent Leishmania parasites in murine lesions using heavy water
645 labeling. *PLoS Pathog* **11**, e1004683.

646 Knodler, L.A. (2015). Salmonella enterica: living a double life in epithelial cells. *Curr Opin Microbiol*
647 **23**, 23-31.

648 Knodler, L.A., Crowley, S.M., Sham, H.P., Yang, H., Wrande, M., Ma, C., *et al.* (2014). Noncanonical
649 inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against
650 enteric bacterial pathogens. *Cell Host Microbe* **16**, 249-256.

651 Knodler, L.A., Vallance, B.A., Celli, J., Winfree, S., Hansen, B., Montero, M. and Steele-Mortimer, O.
652 (2010). Dissemination of invasive Salmonella via bacterial-induced extrusion of mucosal
653 epithelia. *Proc Natl Acad Sci U S A* **107**, 17733-17738.

654 Kreibich, S. and Hardt, W.D. (2015). Experimental approaches to phenotypic diversity in infection.
655 *Curr Opin Microbiol* **27**, 25-36.

656 Kullas, A.L., McClelland, M., Yang, H.J., Tam, J.W., Torres, A., Porwollik, S., *et al.* (2012). L-
657 asparaginase II produced by Salmonella typhimurium inhibits T cell responses and mediates
658 virulence. *Cell Host Microbe* **12**, 791-798.

659 Lahiri, A., Das, P. and Chakravorty, D. (2008). Arginase modulates Salmonella induced nitric oxide
660 production in RAW264.7 macrophages and is required for Salmonella pathogenesis in mice
661 model of infection. *Microbes Infect* **10**, 1166-1174.

662 LaRock, D.L., Chaudhary, A. and Miller, S.I. (2015). Salmonellae interactions with host processes. *Nat*
663 *Rev Microbiol* **13**, 191-205.

664 Lathrop, S.K., Binder, K.A., Starr, T., Cooper, K.G., Chong, A., Carmody, A.B. and Steele-Mortimer, O.
665 (2015). Replication of Salmonella enterica Serovar Typhimurium in Human Monocyte-
666 Derived Macrophages. *Infect Immun* **83**, 2661-2671.

667 Lee, E.J., Choi, J. and Groisman, E.A. (2014). Control of a Salmonella virulence operon by proline-
668 charged tRNA(Pro). *Proc Natl Acad Sci U S A* **111**, 3140-3145.

669 Lee, E.J., Pontes, M.H. and Groisman, E.A. (2013). A bacterial virulence protein promotes
670 pathogenicity by inhibiting the bacterium's own F1Fo ATP synthase. *Cell* **154**, 146-156.

671 Lim, C.H., Voedisch, S., Wahl, B., Rouf, S.F., Geffers, R., Rhen, M. and Pabst, O. (2014). Independent
672 bottlenecks characterize colonization of systemic compartments and gut lymphoid tissue by
673 salmonella. *PLoS Pathog* **10**, e1004270.

674 Liss, V., Swart, A.L., Kehl, A., Hermanns, N., Zhang, Y., Chikkaballi, D., *et al.* (2017). Salmonella
675 enterica Remodels the Host Cell Endosomal System for Efficient Intravacuolar Nutrition. *Cell*
676 *Host Microbe* **21**, 390-402.

677 Liu, Y., Yu, K., Zhou, F., Ding, T., Yang, Y., Hu, M. and Liu, X. (2017). Quantitative Proteomics Charts
678 the Landscape of Salmonella Carbon Metabolism within Host Epithelial Cells. *J Proteome Res*
679 **16**, 788-797.

680 Lorkowski, M., Felipe-Lopez, A., Danzer, C.A., Hansmeier, N. and Hensel, M. (2014). Salmonella
681 enterica invasion of polarized epithelial cells is a highly cooperative effort. *Infect Immun* **82**,
682 2657-2667.

683 Maier, L., Barthel, M., Stecher, B., Maier, R.J., Gunn, J.S. and Hardt, W.D. (2014). Salmonella
684 Typhimurium strain ATCC14028 requires H₂-hydrogenases for growth in the gut, but not at
685 systemic sites. *PLoS One* **9**, e110187.

686 Maier, L., Vyas, R., Cordova, C.D., Lindsay, H., Schmidt, T.S., Brugiroux, S., *et al.* (2013). Microbiota-
687 derived hydrogen fuels Salmonella typhimurium invasion of the gut ecosystem. *Cell Host*
688 *Microbe* **14**, 641-651.

689 Maze, A., Glatter, T. and Bumann, D. (2014). The central metabolism regulator EIIAGlc switches
690 Salmonella from growth arrest to acute virulence through activation of virulence factor
691 secretion. *Cell reports* **7**, 1426-1433.

692 McQuate, S.E., Young, A.M., Silva-Herzog, E., Bunker, E., Hernandez, M., de Chaumont, F., *et al.*
693 (2017). Long-term live-cell imaging reveals new roles for Salmonella effector proteins SseG
694 and SteA. *Cell Microbiol* **19**.

695 Meynell, G.G. (1957). The applicability of the hypothesis of independent action to fatal infections in
696 mice given Salmonella typhimurium by mouth. *J Gen Microbiol* **16**, 396-404.

697 Michelucci, A., Cordes, T., Ghelfi, J., Pailot, A., Reiling, N., Goldmann, O., *et al.* (2013). Immune-
698 responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid
699 production. *Proc Natl Acad Sci U S A* **110**, 7820-7825.

700 Mills, E. and Avraham, R. (2017). Breaking the population barrier by single cell analysis: one host
701 against one pathogen. *Curr Opin Microbiol* **36**, 69-75.

702 Monahan, L.G. and Harry, E.J. (2016). You Are What You Eat: Metabolic Control of Bacterial Division.
703 *Trends Microbiol* **24**, 181-189.

704 Olive, A.J. and Sasseti, C.M. (2016). Metabolic crosstalk between host and pathogen: sensing,
705 adapting and competing. *Nat Rev Microbiol* **14**, 221-234.

706 Pavlova, N.N. and Thompson, C.B. (2016). The Emerging Hallmarks of Cancer Metabolism. *Cell*
707 *metabolism* **23**, 27-47.

708 Petras, D., Jarmusch, A.K. and Dorrestein, P.C. (2017). From single cells to our planet-recent
709 advances in using mass spectrometry for spatially resolved metabolomics. *Curr Opin Chem*
710 *Biol* **36**, 24-31.

711 Pontes, M.H., Yeom, J. and Groisman, E.A. (2016). Reducing Ribosome Biosynthesis Promotes
712 Translation during Low Mg²⁺ Stress. *Mol Cell* **64**, 480-492.

713 Popp, J., Noster, J., Busch, K., Kehl, A., Zur Hellen, G. and Hensel, M. (2015). Role of host cell-derived
714 amino acids in nutrition of intracellular Salmonella enterica. *Infect Immun* **83**, 4466-4475.

715 Rivera-Chavez, F. and Baumler, A.J. (2015). The Pyromaniac Inside You: Salmonella Metabolism in
716 the Host Gut. *Annu Rev Microbiol* **69**, 31-48.

717 Rivera-Chavez, F., Zhang, L.F., Faber, F., Lopez, C.A., Byndloss, M.X., Olsan, E.E., *et al.* (2016).
718 Depletion of Butyrate-Producing Clostridia from the Gut Microbiota Drives an Aerobic
719 Luminal Expansion of Salmonella. *Cell Host Microbe* **19**, 443-454.

720 Saliba, A.E., Li, L., Westermann, A.J., Appenzeller, S., Stapels, D.A., Schulte, L.N., *et al.* (2016). Single-
721 cell RNA-seq ties macrophage polarization to growth rate of intracellular Salmonella. *Nature*
722 *microbiology* **2**, 16206.

723 Saliba, A.E., S, C.S. and Vogel, J. (2017). New RNA-seq approaches for the study of bacterial
724 pathogens. *Curr Opin Microbiol* **35**, 78-87.

725 Santos, R.L., Zhang, S., Tsolis, R.M., Kingsley, R.A., Adams, L.G. and Baumler, A.J. (2001). Animal
726 models of Salmonella infections: enteritis versus typhoid fever. *Microbes.Infect.* **3**, 1335-
727 1344.

728 Sauer, U. (2006). Metabolic networks in motion: 13C-based flux analysis. *Mol Syst Biol* **2**, 62.

729 Schubert, O.T., Ludwig, C., Kogadeeva, M., Zimmermann, M., Rosenberger, G., Gengenbacher, M., *et*
730 *al.* (2015). Absolute Proteome Composition and Dynamics during Dormancy and
731 Resuscitation of Mycobacterium tuberculosis. *Cell Host Microbe* **18**, 96-108.

732 Schurmann, N., Forrer, P., Casse, O., Li, J., Felmy, B., Burgener, A.V., *et al.* (2017). Myeloperoxidase
733 targets oxidative host attacks to Salmonella and prevents collateral tissue damage. *Nature*
734 *microbiology* **2**, 16268.

735 Sellin, M.E., Muller, A.A., Felmy, B., Dolowschiak, T., Diard, M., Tardivel, A., *et al.* (2014). Epithelium-
736 Intrinsic NAIP/NLRC4 Inflammasome Drives Infected Enterocyte Expulsion to Restrict
737 Salmonella Replication in the Intestinal Mucosa. *Cell host & microbe* **16**, 237-248.

738 Singh, V., Finke-Isami, J., Hopper-Chidlaw, A.C., Schwerk, P., Thompson, A. and Tedin, K. (2017).
739 Salmonella Co-opts Host Cell Chaperone-mediated Autophagy for Intracellular Growth. *J Biol*
740 *Chem* **292**, 1847-1864.

741 Slauch, J.M. (2011). How does the oxidative burst of macrophages kill bacteria? Still an open
742 question. *Mol Microbiol* **80**, 580-583.

743 Steeb, B., Claudi, B., Burton, N.A., Tienz, P., Schmidt, A., Farhan, H., *et al.* (2013). Parallel exploitation
744 of diverse host nutrients enhances salmonella virulence. *PLoS Pathog* **9**, e1003301.

745 Tchawa Yimga, M., Leatham, M.P., Allen, J.H., Laux, D.C., Conway, T. and Cohen, P.S. (2006). Role of
746 gluconeogenesis and the tricarboxylic acid cycle in the virulence of *Salmonella enterica*
747 serovar Typhimurium in BALB/c mice. *Infect Immun* **74**, 1130-1140.

748 Tennant, S.M. and Levine, M.M. (2015). Live attenuated vaccines for invasive *Salmonella* infections.
749 *Vaccine* **33 Suppl 3**, C36-41.

750 Thiele, I., Hyduke, D.R., Steeb, B., Fankam, G., Allen, D.K., Bazzani, S., *et al.* (2011). A community
751 effort towards a knowledge-base and mathematical model of the human pathogen
752 *Salmonella Typhimurium* LT2. *BMC Syst Biol* **5**, 8.

753 Thiennimitr, P., Winter, S.E., Winter, M.G., Xavier, M.N., Tolstikov, V., Huseby, D.L., *et al.* (2011).
754 Intestinal inflammation allows *Salmonella* to use ethanolamine to compete with the
755 microbiota. *Proc Natl Acad Sci U S A* **108**, 17480-17485.

756 Thurston, T.L., Matthews, S.A., Jennings, E., Alix, E., Shao, F., Shenoy, A.R., *et al.* (2016). Growth
757 inhibition of cytosolic *Salmonella* by caspase-1 and caspase-11 precedes host cell death. *Nat*
758 *Commun* **7**, 13292.

759 Turner, A.K., Barber, L.Z., Wigley, P., Muhammad, S., Jones, M.A., Lovell, M.A., *et al.* (2003).
760 Contribution of proton-translocating proteins to the virulence of *Salmonella enterica*
761 serovars Typhimurium, Gallinarum, and Dublin in chickens and mice. *Infect.Immun.* **71**, 3392-
762 3401.

763 Vorwerk, S., Krieger, V., Deiwick, J., Hensel, M. and Hansmeier, N. (2015). Proteomes of host cell
764 membranes modified by intracellular activities of *Salmonella enterica*. *Mol Cell Proteomics*
765 **14**, 81-92.

766 Waddington, C.S., Darton, T.C., Jones, C., Haworth, K., Peters, A., John, T., *et al.* (2014). An
767 outpatient, ambulant-design, controlled human infection model using escalating doses of
768 *Salmonella Typhi* challenge delivered in sodium bicarbonate solution. *Clinical infectious*
769 *diseases : an official publication of the Infectious Diseases Society of America* **58**, 1230-1240.

770 Wain, J., Hendriksen, R.S., Mikoleit, M.L., Keddy, K.H. and Ochiai, R.L. (2015). Typhoid fever. *Lancet*
771 **385**, 1136-1145.

772 Wang, C.Z., Kazmierczak, R.A. and Eisenstark, A. (2016). Strains, Mechanism, and Perspective:
773 *Salmonella*-Based Cancer Therapy. *International journal of microbiology* **2016**, 5678702.

774 Winter, S.E., Thiennimitr, P., Winter, M.G., Butler, B.P., Huseby, D.L., Crawford, R.W., *et al.* (2010).
775 Gut inflammation provides a respiratory electron acceptor for *Salmonella*. *Nature* **467**, 426-
776 429.

777 Wotzka, S.Y., Nguyen, B.D. and Hardt, W.D. (2017). *Salmonella Typhimurium* Diarrhea Reveals Basic
778 Principles of Enteropathogen Infection and Disease-Promoted DNA Exchange. *Cell Host*
779 *Microbe* **21**, 443-454.


780 Wrande, M., Andrews-Polymenis, H., Twedt, D.J., Steele-Mortimer, O., Porwollik, S., McClelland, M.
781 and Knodler, L.A. (2016). Genetic Determinants of *Salmonella enterica* Serovar Typhimurium
782 Proliferation in the Cytosol of Epithelial Cells. *Infect Immun* **84**, 3517-3526.

783 Zampieri, M., Sekar, K., Zamboni, N. and Sauer, U. (2017). Frontiers of high-throughput
784 metabolomics. *Curr Opin Chem Biol* **36**, 15-23.

785 Zhang, K., Dupont, A., Torow, N., Gohde, F., Leschner, S., Lienenklaus, S., *et al.* (2014). Age-
786 dependent enterocyte invasion and microcolony formation by *Salmonella*. *PLoS Pathog* **10**,
787 e1004385.

788

789




791

792 **Figure 1:** Evidence for core *Salmonella* metabolic activities and nutrient supply routes.

793 **A)** Experimental evidence for *Salmonella* intracellular metabolism in various cell culture
794 models and during systemic salmonellosis in the mouse typhoid fever model. Data for
795 intracellular growth, glucose as a major nutrient, key metabolic pathways (EMP, Embden-
796 Meyerhof-Parnas pathway; TCA, tricarboxylic acid cycle; Aerob Resp, aerobic respiration),
797 and the role of *Salmonella*-induced filaments (Sif) for nutrient supply are shown (++, strong
798 effect; 1, significant but moderate effect, -, no detectable impact; --, growth-diminishing
799 effect). Data were collected from various studies (¹(Knodler *et al.*, 2010), ²(Holzer *et al.*,
800 2012), ³(Helaine *et al.*, 2010), ⁴(Claudi *et al.*, 2014), ⁵(Bowden *et al.*, 2009), ⁶(Bowden *et al.*,
801 2014), ⁷(Garcia-Gutierrez *et al.*, 2016), ⁸(Singh *et al.*, 2017), ⁹(Steeb *et al.*, 2013), ¹⁰(Bowden
802 *et al.*, 2010), ¹¹(Tchawa Yimga *et al.*, 2006), ¹²(Becker *et al.*, 2006), ¹³(Craig *et al.*, 2013),
803 ¹⁴(Popp *et al.*, 2015), ¹⁵(Liss *et al.*, 2017), ¹⁶(Lathrop *et al.*, 2015), ¹⁷(Grant *et al.*, 2012)).

804 **B)** Possible supply routes for host nutrients and toxic molecules in *Salmonella*-infected cells.
805 Orange symbols represent various compounds.

806



807

808

809 **Figure 2:** Experimental evidence for nutrient supply and enzyme essentiality for *Salmonella*
 810 during systemic salmonellosis in the mouse typhoid fever model. On top, nutrients are shown
 811 with font size corresponding to differential supply rates. The *Salmonella* metabolism network
 812 is shown below in a schematic overview with lines (representing enzymes) connecting
 813 symbols (metabolites). Enzymes are shown in different colors that represent enzyme
 814 relevance for *Salmonella* in vivo fitness. A fully annotated version of this scheme is available
 815 at http://www.biozentrum.unibas.ch/personal/bumann/steeb_et_al/index.html.